Quantum Safe Cryptography for Pharma: Protecting Clinical Trial Data for Decades

Pharma's 25+ Year Confidentiality Problem

Clinical trial data, New Drug Application (NDA) submissions, and Investigational New Drug (IND) filings remain confidential and commercially sensitive for decades. FDA 21 CFR Part 11 governs the electronic records/signatures framework, while predicate rules (21 CFR 312.62 for IND, 314.81 for NDA) set retention periods that often exceed 25 years.

FDA 21 CFR Part 11 Final Guidance (October 2024)

FDA finalized updated Part 11 guidance in October 2024 for electronic systems, records, and signatures in clinical investigations. The guidance emphasizes the need for cryptographic integrity of trial data across the entire lifecycle, which increasingly means addressing future quantum threats.

Applying Mosca's Theorem to Pharma

• X: 25+ years for clinical trial archives, patent-life-protected NDA data, genetic data.
• Y: 3-5 years for large pharma migration.
• Z: 10-20 years per GRI 2025.

For nearly all long-term pharma data, X+Y>Z holds. HNDL is a realistic threat against clinical trial datasets that competitors or foreign intelligence services could weaponize years after the patent expires.

What Pharma Organizations Should Do

1. Inventory cryptography in clinical data management systems (eCRF, EDC, LIMS).
2. Deploy hybrid ML-KEM on new CROs and eTMF systems.
3. Encrypt archived trial data with Post Quantum Cryptography before HNDL harvesting becomes decryptable.
4. Update BAAs with CROs requiring PQC roadmaps.

Frequently Asked Questions

How long must pharma retain clinical trial data?

Varies by document type. Predicate rules (21 CFR 312.62 for IND, 314.81 for NDA) often require 25+ years. Some records effectively require indefinite retention.

Does FDA 21 CFR Part 11 mandate PQC?

Not explicitly as of April 2026. FDA finalized Part 11 guidance October 2024 emphasizing electronic record integrity. Expect PQC-specific guidance by 2027-2029.

Is genetic data particularly sensitive?

Yes. Genetic data remains identifying across generations. Combined with HNDL, genetic data encrypted today with RSA or ECDH is at severe long-term risk.

Should pharma use FIPS-validated cryptography?

Yes. Pharma regulated systems typically require FIPS 140-3 validated modules. PQC modules validated under FIPS 203/204/205 are becoming available through 2026-2027.

Sources

1. FDA Part 11 Guidance (Oct 2024)
2. FIPS 203

Related Articles

• PQC for Healthcare
• PQC for Insurance
• HNDL
• Mosca's Theorem
• Implementing PQC